Name: Latest research reports of Hikal Ltd. authored by BP Wealth and published by - Trendlyne research reports.
Item: Hikal Ltd.
Rating: 1
Author: BP Wealth

Hikal Ltd.

NSE: HIKAL | BSE: 524735 | ISIN: INE475B01022 | Industry: Pharmaceuticals
| Expensive Star

425.6500 7.00 (1.67%)

NSE Apr 03, 2025 15:31 PM

59.27% Gain from 52W Low

Volume: 365.1K

Hikal Ltd.

29 Oct 2019

425.65

1.67%

BP Equities Hikal Ltd Q2FY20 Result Update

Sell: Hikal Ltd.

BP Wealth

custom duty) of INR154mn. The company posted revenues of INR 3,211mn with 18.7% YoY decline which was below our estimate of INR,4,845mn. Multiple factors affected revenue growth during the quarter such as 1) Crop protection business was affected by heavy flooding at Mahad facility in the month of august which led to temporary production shut down.2) Pharmaceutical business faced issue at taloja facility where MIDC had cut 50% of the water supply to all industries in that region during Q2 and destocking of some of the products by innovator clients led to postponement in product...

Hikal Ltd. has gained 21.37% in the last 1 Month